Studies

Non-metastatic

Currently no open trials

Metastatic

First line
Delphi 312 (Amgen)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and  Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

Second line
IDeate-Lung02 (Daichi Sankyo) (DS7300-188)
A phase 3, multicenter, randomized,open-label study of ifinatamab deruxtecan (idxd), a b7-h3 antibody-drug conjugate (adc), versus treatment of physician’s choice (topotecan) in subjects with relapsed small cell lung cancer

EVOKE-SCLC-04 (Gilead)
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With PreviouslyTreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Resectable

Neo-coast2 (Astra Zeneca)
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

KRASG12c + NSCLC: SUNRAY-02 (Lilly)
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Pts with Resected or Unresectable KRAS G12C-Mutant, NSCLC (JZQH)

Unresectable

SUNRAY-02 (Lilly) : open end of 2025
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Pts with Resected or Unresectable KRAS G12C-Mutant, NSCLC (JZQH)

1st line

Artemide 
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Squamous
Currently no open trials

Non-squamous
Relativity CA224-1093 (BMS)
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Nonsmall Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1%

AndroMETa M24-536 (ABBVIE): part 2 open end of 2025
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) 

Pulse: maintenance (academic)
Maintenance Pembrolizumab at usual or low dose non-squamous lung cancer: a non-inferiority study.

2nd + line

Artemia (OSE Immunotherapeutics)
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic NonSmall Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitors (ICI)

Ability NSCLC-06 (genmab)
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Pulmo (iOnctura)
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in patients with advanced non-squamous NSCLC who have progressed on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy.

EGFR common exon 19 or exon 21 mutation

1st line
LAT-FLOSI (Academic)
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib (LATFLOSI).

2nd + line
TROPION-LUNG15 (Astra Zeneca)
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

EGFR exon 20 insertion mutation

1st line
REZILIENT3 (Taiho Oncology)
Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

HER2 mutation

1st line
SOHO-2 Bayer
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC With HER2-activating Mutations.

MET exon 14 skipping mutation

Currently no open trials

(K)RAS mutation

1st line
KRASG12c mutation: PDL1<1% (Roche)
Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of divarasib in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a kras g12c mutation

2nd + line
All RAS mutations (RMC-6236-301): (Revolution Medicine)
Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

ALK fusion

Currently no open trials

BRAF mutation

Currently no open trials

Other trials

Allies
Muscle mass in patients with colorectal or lung cancer when receiving a n-3 PUFA and leucine enriched high protein and high energy oral nutritional supplement during anticancer treatment

Tropion lung 4

Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) (Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer)

Krascendo1:

Phase III randomised, open label , multicenter study evaluating the efficacy and safety of divarasib versus sotarasib in patients with previously treated kras G12C positive advanced or metastatic non-small cell lung cancer
 

Inhaled cisplatinum (inhatarget)

A Phase I/IIa First-in-Human Single-arm Open-label Multicentre Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Cisplatin-based Formulation Administered as Dry Powder for Inhalation in Combination with First Line Standard of Care in Patients with Stage IV NonSmall Cell Lung Cancer

ASPIRE

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough.

TILIA

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)